How a poorly explored immune cell may impact cancer immunity and immunotherapy

November 17, 2017, University of Michigan
Tumor cells secrete lactate (blue dots) that makes contact with naïve T cells and contributes to FIP200 expression that disables the balance between pro-apoptotic and anti-apoptotic gene expression in the cells. Credit: Xia et al., Sci. Immunol. 2, eaan4631 (2017)

The immune cells that are trained to fight off the body's invaders can become defective. It's what allows cancer to develop. So most research has targeted these co-called effector T-cells.

But a new study takes a step back and considers: What if the problem isn't with the effector T-cells but starts higher up the cellular chain?

And so researchers looked at naïve T-cells - a type of immune cell that hasn't yet been triggered to fight. Naïve T-cells differentiate into the fighter effector T-cells.

"People didn't realize the problem may not only be directly from the effector cells themselves, but may also stem from a defect in the naïve cells. We found naïve cells already have a problem in patients who have cancer. If the naïve cells are functionally impaired, the cannot be healthy," says study author Weiping Zou, M.D., Ph.D., the Charles B. de Nancrede Professor of Surgery, Pathology, Immunology and Biology at the University of Michigan.

Naïve T-cells are not well understood in cancer, in part because the effector T-cells have direct control over immunity. So that's where researchers have focused their attention. Also, naïve T-cells are rare in the tumor microenvironment - the traditional battlefield between cancer and .

The new study, published in Science Immunology, finds that tumor metabolism impacts naïve T-cells. The use a lot of glucose. When the glucose is metabolized, it produces lactate - and lactate turns out to be very bad for naïve T-cells. Once the tumor produces a certain level of lactate, it causes damage to the naïve T-cells, including cell death.

Currently, efforts to predict response to immunotherapy focus on memory and effector T-cells. The new research suggests another path.

"Yes, you do see problems in effector T-cells, but you have to keep in mind that to begin with, the naïve T-cells are functionally impaired by the tumor metabolism," Zou says.

Researchers will look for ways to manipulate the metabolism to try to recover the function of the naïve T-cells in the hopes that it can make immunotherapy more effective. Some early phase clinical trials are testing a way to target the lactate pathway. Researchers hope this could provide a rationale for combining immunotherapy with a therapy to regulate metabolism.

"When you have more healthy naïve T-cells to begin with, hopefully you will get more healthy effector T-cells, which will overcome some of the resistance we see with immunotherapy," Zou says.

Explore further: Scientists discover surprising immune cell activity that may be limiting immunotherapy

More information: H. Xia el al., "Suppression of FIP200 and autophagy by tumor derived lactate promotes naïve T cell apoptosis and affects tumor immunity," Science Immunology (2017). immunology.sciencemag.org/look … 6/sciimmunol.aan4631

Related Stories

Scientists discover surprising immune cell activity that may be limiting immunotherapy

October 30, 2017
Researchers have uncovered a surprising process within a key immune cell that may help explain the limitations of immunotherapy as a cancer treatment.

Beta-adrenergic receptor signaling affects tumor microenvironment

September 13, 2017
(HealthDay)—β2-adrenergic receptor (β-AR) signaling in host immune cells regulates CD8+ T-cell frequency and functional orientation within the tumor microenvironment, according to a study published online Aug. 17 in Cancer ...

New memory for HIV patients

March 26, 2012
The hallmark loss of helper CD4+ T cells during human immunodeficiency virus (HIV) infection may be a red herring for therapeutics, according to a study published on March 26th in the Journal of Experimental Medicine.

Boosting immunity in older adults: Study unmasks new infection-fighting T cells

June 13, 2016
Sixty-five is the age when many people retire, kick back and take it easy. And so it often is with the human immune system.

Balancing T cell populations

November 25, 2013
Depending on the signals received, naïve T cells are able to differentiate into mature T cell populations, which play different roles in the immune system. For example, regulatory T cells (Tregs) are important for tamping ...

Recommended for you

Macrophage cells key to helping heart repair—and potentially regenerate, new study finds

December 11, 2018
Scientists at the Peter Munk Cardiac Centre have identified the type of cell key to helping the heart repair and potentially regenerate following a heart attack.

Researchers discover unique immune cell likely drives chronic inflammation

December 11, 2018
For the first time, researchers have identified that an immune cell subset called gamma delta T cells that may be causing and/or perpetuating the systemic inflammation found in normal aging in the general geriatric population ...

New light-based technology reveals how cells communicate in human disease

December 11, 2018
Scientists at the University of York have developed a new technique that uses light to understand how cells communicate in human disease.

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Immune cells sacrifice themselves to protect us from invading bacteria

December 11, 2018
Immune systems are working overtime as winter approaches. Stomach flu can turn the strongest individual into a bedridden convalescent. Viruses are spreading in kindergartens. This year's flu is approaching in full swing. ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.